Los Angeles Capital Management
TRVI icon

Los Angeles Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Los Angeles Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
555
– – ﹤0.01% 1955
2026
Q1 		$6.62K Buy
555
+468
+538% +$5.24K ﹤0.01% 2049
2025
Q4 		$972 Buy
+87
New +$1K ﹤0.01% 2479
2025
Q3 		– Sell
-16,379
Closed -$89.6K – 1535
2025
Q2 		$89.6K Buy
+16,379
New +$102K ﹤0.01% 1261

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Los Angeles Capital Management's TRVI Position: Q2 2026 in Review

Los Angeles Capital Management held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 555 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Los Angeles Capital Management first reported a position in TRVI in Q2 2025 and has held it in 4 quarters since. The position peaked at $89.6K in Q2 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Los Angeles Capital Management held 555 shares of Trevi Therapeutics worth $10.4K as of Q2 2026.
  • Los Angeles Capital Management left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1955 holding.
  • Los Angeles Capital Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Trevi Therapeutics position peaked at $89.6K in Q2 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.